

Q7 human fetal kidney cells, BALL-1 and the like for human leukemia cells, and COS-1, COS-7 and the like for African green monkey kidney cells.

Page 43, fifth paragraph starting on line 22,

Q8 Examples of the thus obtained protein include a protein comprising the amino acid sequences represented by SEQ ID NOS:3, 4, 5 and 6.

Page 43, sixth paragraph starting on line 25 and continuing to page 44,

Q9 Furthermore, a fusion protein of the protein of the present invention and other protein may be produced, and purified by affinity chromatography using a substance having affinity to the fusion protein. For example, the protein of the present invention may be produced as a fusion protein with protein A according to the method of Lowe *et al.* (*Proc. Natl. Acad. Sci. USA*, 86: 8227 (1989); *Genes Develop.*, 4: 1288 (1990)), or the method described in Japanese Published Unexamined Patent Application No. 336963/93 or WO 94/23021, and purified by affinity chromatography using immunoglobulin G.

IN THE CLAIMS

Kindly enter the following amended claims.

Q9 12. (Amended) The DNA according to claim 4 wherein the DNA encoding a polypeptide having β -ketoacyl-ACP synthase activity is:
a DNA comprising comprising the nucleotide sequence selected from the group consisting of nucleotide Nos. 1441-2742, 6256-7545, 12076-13368, 15217-16506, 20008-21297 and 24781-26079 of SEQ ID NO: 1, and nucleotide Nos. 100-1383, 4771-6060, 7906-9258, 14935-16224, 20413-21705 and 25810-27102 of SEQ ID NO: 2; or
a DNA which hybridizes with said DNA under stringent conditions and which encodes a polypeptide having β -ketoacyl-ACP synthase activity.

Q10

26. (Amended) A DNA comprising the nucleotide sequence selected from the group consisting of nucleotide Nos. 1441-2742, 6256-7545, 12076-13368, 15217-16506, 20008-21297, and 24781-26079 of SEQ ID NO: 1 and nucleotide Nos. 100-1383, 4771-6060, 7906-9258, 14935-16224, 20413-21705 and 25810-27102 of SEQ ID NO: 2; or
a DNA which hybridizes with said DNA under stringent conditions and which encodes a polypeptide having β -ketoacyl-ACP synthase activity

Q11
09014286-082401
104280-98241560

33. (Amended) A polypeptide comprising the amino acid sequence selected from the group consisting of amino acid Nos. 29-344, 366-451, 481-914, 1050-1356, 1715-1892, 1979-2060, 2086-2515, 2983-3128, 3537-3714 and 3805-3886 of SEQ ID NO: 3, amino acid Nos. 36-466, 596-908, 978-1059, 1083-1512, 1653-1964, 2306-2483, 2575-2656, 2680-3109, 3230-3538, 3878-4056, 4159-4240, 4271-4703, 4815-5122, 5168-5307, 5753-5930 and 6032-6113 of SEQ ID NO: 4, amino acid Nos. 34-461, 550-891, 1212-1396, 1483-1564, 1591-2020, 2108-2448, 2525-2606, 2636-3086, 3226-3591, 3629-3763, 4183-4363, 4460-4553 and 4627-4873 of SEQ ID NO: 5, amino acid Nos. 38-467, 574-914, 956-1081, 1488-1673, 1756-1837, 1864-2294, 2390-2732, 2776-2902, 3288-3473, 3556-3637, 3663-4093, 4182-4523, 4565-4685, 5085-5270 and 5353-5434 of SEQ ID NO: 6; or
a polypeptide comprising an amino acid sequence wherein one or more amino acids are deleted, replaced or added in the amino acid sequence selected above, and having avermectin aglycon synthase domain activity.

IN THE SEQUENCE LISTING

Kindly enter the attached substitute paper and computer readable forms of the Sequence Listing in lieu of the Sequence Listing submitted on August 24, 2001.